• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Incyte

    < Previous 1 2 3 4 Next >
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Report First Quarter Financial Results
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)
    From Incyte
    Via Business Wire
    Tickers INCY
    Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with Myelofibrosis
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Present at Upcoming Investor Conference
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis Suppurativa
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Present at Upcoming Investor Conference
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Report Fourth Quarter and Year-End 2022 Financial Results
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Present at Upcoming Investor Conferences
    From Incyte
    Via Business Wire
    Tickers INCY
    Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
    From Incyte
    Via Business Wire
    Tickers INCY
    More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
    From Incyte
    Via Business Wire
    Tickers INCY
    Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Report Third Quarter Financial Results
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Names New Member to Its Board of Directors
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
    From Incyte
    Via Business Wire
    Tickers INCY
    Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Present at Upcoming Investor Conference
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
    From Incyte
    Via Business Wire
    Tickers INCY
    Incyte to Report Second Quarter Financial Results
    From Incyte
    Via Business Wire
    Tickers INCY
    < Previous 1 2 3 4 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.